How do pre-allo-HSCT conditioning regimens impact GvHD outcomes in myelofibrosis patients?

During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, how do pre-allo-HSCT conditioning regimens impact GvHD outcomes in myelofibrosis patients?

In this video, Murthy discusses the factors that can be modified before transplant, including conditioning intensity and conditioning regimens. He also discusses the findings of his teams' study, which was conducted using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, and included adults aged ≥18 years with the diagnosis of myelofibrosis who underwent allo-HSCT between 2009–2019. Lastly, he comments on the role of pre-transplant ruxolitinib.